ProMetic Life Sciences (OTCMKTS:PFSCF – Get Free Report) and Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.
Earnings & Valuation
This table compares ProMetic Life Sciences and Decoy Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProMetic Life Sciences | $36.55 million | 3.49 | -$150.73 million | N/A | N/A |
| Decoy Therapeutics | N/A | N/A | -$5.58 million | ($33.89) | -0.23 |
Analyst Ratings
This is a breakdown of current ratings and price targets for ProMetic Life Sciences and Decoy Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProMetic Life Sciences | 0 | 0 | 0 | 0 | 0.00 |
| Decoy Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
Decoy Therapeutics has a consensus target price of $30.00, indicating a potential upside of 281.68%. Given Decoy Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Decoy Therapeutics is more favorable than ProMetic Life Sciences.
Profitability
This table compares ProMetic Life Sciences and Decoy Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProMetic Life Sciences | -894.02% | -3,350.55% | -67.76% |
| Decoy Therapeutics | N/A | -401.05% | -155.77% |
Insider & Institutional Ownership
0.1% of ProMetic Life Sciences shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 0.3% of Decoy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
ProMetic Life Sciences has a beta of 2.46, suggesting that its share price is 146% more volatile than the S&P 500. Comparatively, Decoy Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.
Summary
Decoy Therapeutics beats ProMetic Life Sciences on 8 of the 11 factors compared between the two stocks.
About ProMetic Life Sciences
Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.
About Decoy Therapeutics
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
